Latest Insider Transactions at Prometheus Biosciences, Inc. (RXDX)
This section provides a real-time view of insider transactions for Prometheus Biosciences, Inc. (RXDX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Prometheus Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Prometheus Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 09
2022
|
Mark Stenhouse Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,811
+27.06%
|
-
|
|
Apr 05
2022
|
Sinai Intellectual Property CO Cedars > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
142,376
-2.84%
|
-
|
|
Dec 01
2021
|
Mark C. Mc Kenna Chairman, President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+50.0%
|
$30,800
$2.9 P/Share
|
|
Mar 16
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
375,000
+14.43%
|
$7,125,000
$19.0 P/Share
|
|
Mar 16
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,848,022
+50.0%
|
-
|
|
Mar 16
2021
|
Point72 Biotech Private Investments, LLC |
BUY
Open market or private purchase
|
Indirect |
800,000
+23.2%
|
$15,200,000
$19.0 P/Share
|
|
Mar 16
2021
|
Point72 Biotech Private Investments, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,848,024
+43.49%
|
-
|
|
Mar 16
2021
|
Helen C. Adams Director |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$9,500
$19.0 P/Share
|
|
Mar 16
2021
|
Joseph C Papa Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$285,000
$19.0 P/Share
|
|
Mar 16
2021
|
Mark Stenhouse Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
14,000
+50.0%
|
$266,000
$19.0 P/Share
|
|
Mar 16
2021
|
Tadataka Yamada Director |
BUY
Conversion of derivative security
|
Direct |
13,333
+50.0%
|
-
|
|
Mar 16
2021
|
Sinai Medical Center Cedars > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,416,008
+19.92%
|
-
|
|
Mar 16
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,464,031
+33.3%
|
-
|
|
Mar 16
2021
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
800,000
+50.0%
|
$15,200,000
$19.0 P/Share
|
|
Mar 16
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
850,000
+20.41%
|
$16,150,000
$19.0 P/Share
|
|
Mar 16
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,464,032
+43.49%
|
-
|